Tianjin Huahong Technology Co., Ltd. appears in FDA records as the legal applicant on premarket notifications for blood lancets regulated under 21 CFR 878.4850 in Class II, product code FMK, with the review panel listed as General and Plastic Surgery. The supplied collection holds one linked 510(k) record, K262526, decided Substantially Equivalent on 2026-09-13; that count is an as-of snapshot of the supplied filings, not a measure of total company sales, total portfolio or safety performance. The company describes itself, on its own websites, as a developer, manufacturer and marketer of capillary blood sampling devices. [1][2][3][5]
Documented FDA clearances
K262526 covers a device named Safety lancet (XL), received 2026-07-22 and decided 2026-09-13 as Substantially Equivalent under a Traditional clearance type, with a Summary statement and no third-party review. The FDA record lists the applicant as Tianjin Huahong Technology Co., Ltd. at A01, Plant B, #278, Hangkong Rd., Tianjin Pilot Free Trade Zone, and gives the device classification as Single Use Only Blood Lancet With An Integral Sharps Injury Prevention Feature. [1][2]
Other numbered sources show the same applicant on separate lancet submissions: K252490 for Heel Stick Safety Lancet (HHZ-II, HHZ-III, HHZ-IV), dated February 12, 2026, and K260191 for Safety lancet (XXXVII), dated March 31, 2026, both under 21 CFR 878.4850, Class II, product code FMK. K260191 names K240806, a Safety Lancet by Tianjin Huahong Technology Co., Ltd., as a predicate device. [4][7]
Product scope as published by the company
The company's own site describes production of safe and accurate capillary blood sampling and injection products such as blood lancet devices, pen needles and lancing devices, with quality control framed around reducing discomfort and improving safety. A separate product page describes the company as a supplier of capillary blood sampling devices and injection products, specializing in disposable medical devices including various blood lancets, pen needles and lancing devices. [3][6]
Company-published history states that Huahong has developed, manufactured and marketed capillary blood sampling devices since 2010, that it was the first enterprise in China to automate lancet production, and that its products have been distributed in countries including the USA, Canada, Europe, Korea, Japan, Brazil and Africa. These are company statements, not independently verified findings. [5][9]
Applicant identity and corporate claims
The FDA legal applicant name on the filings is Tianjin Huahong Technology Co., Ltd., with Ningning Wang listed as contact or registered engineer. The filing address matches the address published on the company's website, but an FDA filing address is not evidence of a headquarters location, and no parent, subsidiary or brand relationship is verified in the public documents. [1][3][4][7]
The company's about page states that it holds over 10 innovation patents and describes a mission of people-oriented value creation; these are publisher claims about the company, not certifications or test results documented in the FDA records. No clinical outcome data, customer list or commercial availability details appear in the public information. [9]
Reading the collection
The supplied portfolio contains one linked record, a 510(k) with decision SESE, and the sample of one record carries the same single SESE decision; both describe the same filing, K262526. The additional submissions cited above come from separate numbered sources and are not counted in that collection total. [1][4][7]
K251694 appears in the sources as a 510(k) record for a Single Use Only Blood Lancet With An Integral Sharps Injury Prevention Feature with a Special review type, but the supplied excerpt does not identify its applicant, so it is not attributed to this company here. [8]
